Alexander Azoy Sells 4,343 Shares of Arcus Biosciences (NYSE:RCUS) Stock

Arcus Biosciences, Inc. (NYSE:RCUS) CAO Alexander Azoy sold 4,343 shares of the firm’s stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $22.25, for a total value of $96,631.75. Following the sale, the chief accounting officer owned 18,531 shares in the company, valued at $412,314.75. This trade represents a 18.99% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Alexander Azoy also recently made the following trade(s):

• On Wednesday, December 17th, Alexander Azoy sold 2,113 shares of Arcus Biosciences stock. The shares were sold at an average price of $22.16, for a total value of $46,824.08.
• On Tuesday, December 16th, Alexander Azoy sold 2,376 shares of Arcus Biosciences stock. The stock was sold at an average price of $21.88, for a total value of $51,986.88.
• On Wednesday, November 26th, Alexander Azoy sold 1,900 shares of Arcus Biosciences stock. The stock was sold at an average price of $26.00, for a total value of $49,400.00.
• On Monday, September 29th, Alexander Azoy sold 2,831 shares of Arcus Biosciences stock. The shares were sold at an average price of $13.00, for a total value of $36,803.00.

Arcus Biosciences Stock Performance

Shares of RCUS stock opened at $21.99 on Friday. The firm’s 50-day simple moving average is $21.10 and its 200-day simple moving average is $14.13. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.65 and a quick ratio of 3.65. Arcus Biosciences, Inc. has a 1-year low of $6.50 and a 1-year high of $26.40. The firm has a market cap of $2.37 billion, a P/E ratio of -6.39 and a beta of 0.75.

Arcus Biosciences (NYSE:RCUS) last released its earnings results on Tuesday, October 28th. The company reported ($1.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.33) by $0.06. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The firm had revenue of $26.00 million during the quarter, compared to the consensus estimate of $19.89 million. During the same period in the previous year, the firm earned ($1.00) earnings per share. Arcus Biosciences’s revenue was down 45.8% compared to the same quarter last year. As a group, equities analysts forecast that Arcus Biosciences, Inc. will post -3.15 EPS for the current year.

Hedge Funds Weigh In On Arcus Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. increased its position in shares of Arcus Biosciences by 106.2% during the first quarter. Goldman Sachs Group Inc. now owns 914,208 shares of the company’s stock worth $7,177,000 after acquiring an additional 470,755 shares during the last quarter. Geode Capital Management LLC grew its stake in Arcus Biosciences by 14.9% during the 2nd quarter. Geode Capital Management LLC now owns 1,596,329 shares of the company’s stock valued at $12,995,000 after purchasing an additional 207,097 shares in the last quarter. Rhumbline Advisers grew its stake in Arcus Biosciences by 14.8% during the 1st quarter. Rhumbline Advisers now owns 182,909 shares of the company’s stock valued at $1,436,000 after purchasing an additional 23,645 shares in the last quarter. Tema Etfs LLC increased its holdings in Arcus Biosciences by 291.2% during the 2nd quarter. Tema Etfs LLC now owns 59,662 shares of the company’s stock worth $486,000 after purchasing an additional 44,411 shares during the last quarter. Finally, Woodline Partners LP raised its position in shares of Arcus Biosciences by 45.5% in the 1st quarter. Woodline Partners LP now owns 5,127,304 shares of the company’s stock valued at $40,249,000 after purchasing an additional 1,603,367 shares in the last quarter. 92.89% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

RCUS has been the topic of several research reports. HC Wainwright increased their target price on Arcus Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Arcus Biosciences in a report on Wednesday, October 8th. Bank of America lifted their price objective on Arcus Biosciences from $17.00 to $26.00 and gave the company a “neutral” rating in a research note on Friday, November 28th. UBS Group reissued a “buy” rating on shares of Arcus Biosciences in a research report on Monday. Finally, The Goldman Sachs Group boosted their price objective on shares of Arcus Biosciences from $14.00 to $16.00 and gave the stock a “neutral” rating in a research note on Thursday, October 30th. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Arcus Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.89.

Arcus Biosciences News Summary

Here are the key news stories impacting Arcus Biosciences this week:

• Positive Sentiment: Arcus will present at the 44th Annual J.P. Morgan Healthcare Conference on Jan. 14, 2026 — a high‑visibility forum that can accelerate investor interest, provide clinical/program updates and attract buy‑side attention ahead of catalysts. Arcus to Present at JPM
• Neutral Sentiment: Recent analyst notes are mixed-to-constructive: some firms raised price targets and UBS/Bank of America reaffirmed coverage, producing a consensus “Moderate Buy” and an elevated average target — this supports upside but depends on upcoming clinical and commercial news. MarketBeat analyst summary
• Negative Sentiment: Significant, clustered insider selling occurred Dec. 16–18: CEO Terry Rosen sold large blocks (multiple filings totaling ~54k shares across two days), and other senior officers (CFO, COO, President, CAO, General Counsel and others) also sold shares — this concentrated executive selling is likely weighing on sentiment and may prompt short‑term selling pressure. See CEO SEC filing for details. CEO Form 4
• Negative Sentiment: Additional insider sales (CAO Alexander Azoy, CFO Robert Goeltz II, COO Jennifer Jarrett, President Juan Jaen, General Counsel Carolyn Tang, and insider Richard Markus) were filed and aggregated to meaningful dollar amounts — investors often interpret broad leadership selling as a negative signal even when trades may be for diversification or tax reasons. InsiderTrades summary

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.